SPP1 and autoimmune disease: Recently, TNC, OPN and common receptor integrin-α9β1 have been identified as promising treatment targets for more autoimmune inflammatory diseases, since both TNC- and OPN-deficient mice have shown resistance against a variety of Th1- and/or Th17-related autoimmune diseases (134).